JP2007508290A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007508290A5 JP2007508290A5 JP2006530734A JP2006530734A JP2007508290A5 JP 2007508290 A5 JP2007508290 A5 JP 2007508290A5 JP 2006530734 A JP2006530734 A JP 2006530734A JP 2006530734 A JP2006530734 A JP 2006530734A JP 2007508290 A5 JP2007508290 A5 JP 2007508290A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- alkyl
- optionally substituted
- substituted
- triazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 27
- 229910052736 halogen Inorganic materials 0.000 claims 27
- 150000002367 halogens Chemical class 0.000 claims 21
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 18
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 239000000651 prodrug Substances 0.000 claims 11
- 229940002612 prodrug Drugs 0.000 claims 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- -1 methylenedioxy Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 3
- 102000001267 GSK3 Human genes 0.000 claims 3
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000007530 Essential hypertension Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 208000013016 Hypoglycemia Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 239000000164 antipsychotic agent Substances 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical group O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- BNKVGZXDUVAYFS-UHFFFAOYSA-N ethyl 4-[(6-tert-butyl-3-oxo-2h-[1,2,4]triazolo[4,3-a]pyrazin-8-yl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC(C(C)(C)C)=CN2C(=O)NN=C12 BNKVGZXDUVAYFS-UHFFFAOYSA-N 0.000 claims 2
- 230000035558 fertility Effects 0.000 claims 2
- 208000024963 hair loss Diseases 0.000 claims 2
- 230000003676 hair loss Effects 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000016273 neuron death Effects 0.000 claims 2
- 239000004090 neuroprotective agent Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000015124 ovarian disease Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 230000019100 sperm motility Effects 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- POLAUOGHQIDJOL-UHFFFAOYSA-N 3-[(6-tert-butyl-3-oxo-2h-[1,2,4]triazolo[4,3-a]pyrazin-8-yl)amino]propanenitrile Chemical compound N#CCCNC1=NC(C(C)(C)C)=CN2C(=O)NN=C21 POLAUOGHQIDJOL-UHFFFAOYSA-N 0.000 claims 1
- ZVICCLKJAFIQPK-UHFFFAOYSA-N 5-methyl-6-propan-2-yl-8-(2-pyridin-3-ylethylamino)-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound C12=NNC(=O)N2C(C)=C(C(C)C)N=C1NCCC1=CC=CN=C1 ZVICCLKJAFIQPK-UHFFFAOYSA-N 0.000 claims 1
- AGKIGFGRCKEUIU-UHFFFAOYSA-N 6-tert-butyl-8-(1-hydroxypropan-2-ylamino)-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound OCC(C)NC1=NC(C(C)(C)C)=CN2C(=O)NN=C12 AGKIGFGRCKEUIU-UHFFFAOYSA-N 0.000 claims 1
- BDHXUVFUQBVLKW-UHFFFAOYSA-N 6-tert-butyl-8-(2-ethylsulfanylethylamino)-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound CCSCCNC1=NC(C(C)(C)C)=CN2C(=O)NN=C12 BDHXUVFUQBVLKW-UHFFFAOYSA-N 0.000 claims 1
- RGSWWBAMGAFCQA-UHFFFAOYSA-N 6-tert-butyl-8-(2-methoxyethylamino)-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound COCCNC1=NC(C(C)(C)C)=CN2C(=O)NN=C12 RGSWWBAMGAFCQA-UHFFFAOYSA-N 0.000 claims 1
- QXUHWSNAOLAIHF-UHFFFAOYSA-N 6-tert-butyl-8-(2-pyridin-3-yloxyethylamino)-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound N=1C(C(C)(C)C)=CN(C(NN=2)=O)C=2C=1NCCOC1=CC=CN=C1 QXUHWSNAOLAIHF-UHFFFAOYSA-N 0.000 claims 1
- OCDKRJXMBSTSLF-UHFFFAOYSA-N 6-tert-butyl-8-(2-pyridin-4-yloxyethylamino)-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound N=1C(C(C)(C)C)=CN(C(NN=2)=O)C=2C=1NCCOC1=CC=NC=C1 OCDKRJXMBSTSLF-UHFFFAOYSA-N 0.000 claims 1
- MADZBIDQNUJHGS-UHFFFAOYSA-N 6-tert-butyl-8-(3-imidazol-1-ylpropylamino)-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound N=1C(C(C)(C)C)=CN(C(NN=2)=O)C=2C=1NCCCN1C=CN=C1 MADZBIDQNUJHGS-UHFFFAOYSA-N 0.000 claims 1
- OVWGZKPAZNUTCZ-UHFFFAOYSA-N 6-tert-butyl-8-(3-methoxypropylamino)-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound COCCCNC1=NC(C(C)(C)C)=CN2C(=O)NN=C12 OVWGZKPAZNUTCZ-UHFFFAOYSA-N 0.000 claims 1
- NSRHZPWFEUPBDQ-UHFFFAOYSA-N 6-tert-butyl-8-(3-morpholin-4-ylpropylamino)-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound N=1C(C(C)(C)C)=CN(C(NN=2)=O)C=2C=1NCCCN1CCOCC1 NSRHZPWFEUPBDQ-UHFFFAOYSA-N 0.000 claims 1
- KXZONCXHEBLIPF-UHFFFAOYSA-N 6-tert-butyl-8-(6-hydroxyhexylamino)-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound OCCCCCCNC1=NC(C(C)(C)C)=CN2C(=O)NN=C21 KXZONCXHEBLIPF-UHFFFAOYSA-N 0.000 claims 1
- GYXFKTYCDZYNGD-UHFFFAOYSA-N 6-tert-butyl-8-(oxolan-2-ylmethylamino)-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound N=1C(C(C)(C)C)=CN(C(NN=2)=O)C=2C=1NCC1CCCO1 GYXFKTYCDZYNGD-UHFFFAOYSA-N 0.000 claims 1
- CYENWPOUSLGVMZ-UHFFFAOYSA-N 6-tert-butyl-8-(pyridin-3-ylmethylamino)-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound N=1C(C(C)(C)C)=CN(C(NN=2)=O)C=2C=1NCC1=CC=CN=C1 CYENWPOUSLGVMZ-UHFFFAOYSA-N 0.000 claims 1
- QUHBCBXUVIHAIR-UHFFFAOYSA-N 6-tert-butyl-8-(pyridin-4-ylmethylamino)-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound N=1C(C(C)(C)C)=CN(C(NN=2)=O)C=2C=1NCC1=CC=NC=C1 QUHBCBXUVIHAIR-UHFFFAOYSA-N 0.000 claims 1
- BGUMMDJJAIJMCP-UHFFFAOYSA-N 6-tert-butyl-8-[(4-nitrophenyl)methylamino]-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound N=1C(C(C)(C)C)=CN(C(NN=2)=O)C=2C=1NCC1=CC=C([N+]([O-])=O)C=C1 BGUMMDJJAIJMCP-UHFFFAOYSA-N 0.000 claims 1
- PLJTUDBAKXBITC-UHFFFAOYSA-N 6-tert-butyl-8-[2-(2-methylpyridin-3-yl)ethylamino]-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound CC1=NC=CC=C1CCNC1=NC(C(C)(C)C)=CN2C(=O)NN=C12 PLJTUDBAKXBITC-UHFFFAOYSA-N 0.000 claims 1
- HIWMBFPGVAHHPE-UHFFFAOYSA-N 6-tert-butyl-8-[2-(2-methylpyridin-3-yl)oxyethylamino]-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound CC1=NC=CC=C1OCCNC1=NC(C(C)(C)C)=CN2C(=O)NN=C12 HIWMBFPGVAHHPE-UHFFFAOYSA-N 0.000 claims 1
- HYQVWXMXOTZEPD-UHFFFAOYSA-N 6-tert-butyl-8-[2-(4-methoxyphenoxy)ethylamino]-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound C1=CC(OC)=CC=C1OCCNC1=NC(C(C)(C)C)=CN2C(=O)NN=C12 HYQVWXMXOTZEPD-UHFFFAOYSA-N 0.000 claims 1
- JWOZTMKXSCELPG-UHFFFAOYSA-N 6-tert-butyl-8-[2-(4-methyl-1h-benzimidazol-2-yl)ethylamino]-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound CC(C)(C)C1=CN2C(=O)NN=C2C(NCCC2=NC=3C=CC=C(C=3N2)C)=N1 JWOZTMKXSCELPG-UHFFFAOYSA-N 0.000 claims 1
- SXHAFJZKPXLKGL-UHFFFAOYSA-N 6-tert-butyl-8-[2-(6-methoxypyridin-3-yl)ethylamino]-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound C1=NC(OC)=CC=C1CCNC1=NC(C(C)(C)C)=CN2C(=O)NN=C12 SXHAFJZKPXLKGL-UHFFFAOYSA-N 0.000 claims 1
- HXZQTJWJZWAEFZ-UHFFFAOYSA-N 6-tert-butyl-8-[2-(6-methylpyridin-3-yl)ethylamino]-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound C1=NC(C)=CC=C1CCNC1=NC(C(C)(C)C)=CN2C(=O)NN=C12 HXZQTJWJZWAEFZ-UHFFFAOYSA-N 0.000 claims 1
- KYWIRYJDXDTYTP-UHFFFAOYSA-N 6-tert-butyl-8-[3-(2-oxopyrrolidin-1-yl)propylamino]-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound N=1C(C(C)(C)C)=CN(C(NN=2)=O)C=2C=1NCCCN1CCCC1=O KYWIRYJDXDTYTP-UHFFFAOYSA-N 0.000 claims 1
- RJFYCUAWRSFYHY-UHFFFAOYSA-N 6-tert-butyl-8-[3-(3,5-dimethylpyrazol-1-yl)propylamino]-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound N1=C(C)C=C(C)N1CCCNC1=NC(C(C)(C)C)=CN2C(=O)NN=C12 RJFYCUAWRSFYHY-UHFFFAOYSA-N 0.000 claims 1
- IMRPZUHUKOZYAK-UHFFFAOYSA-N 8-[2-(1,3-benzothiazol-2-ylamino)ethylamino]-6-tert-butyl-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound C1=CC=C2SC(NCCNC=3C=4N(C(NN=4)=O)C=C(N=3)C(C)(C)C)=NC2=C1 IMRPZUHUKOZYAK-UHFFFAOYSA-N 0.000 claims 1
- WVLKZLVPJXMADI-UHFFFAOYSA-N 8-[2-(3-aminopyridin-2-yl)oxyethylamino]-6-tert-butyl-2h-[1,2,4]triazolo[4,3-a]pyrazin-3-one Chemical compound N=1C(C(C)(C)C)=CN(C(NN=2)=O)C=2C=1NCCOC1=NC=CC=C1N WVLKZLVPJXMADI-UHFFFAOYSA-N 0.000 claims 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 208000036119 Frailty Diseases 0.000 claims 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 claims 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 102000004257 Potassium Channel Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 229940005529 antipsychotics Drugs 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 1
- 229960001058 bupropion Drugs 0.000 claims 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 229960004038 fluvoxamine Drugs 0.000 claims 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229960001952 metrifonate Drugs 0.000 claims 1
- 229960001800 nefazodone Drugs 0.000 claims 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 229960002296 paroxetine Drugs 0.000 claims 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims 1
- 229960001697 physostigmine Drugs 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 108020001213 potassium channel Proteins 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 1
- 239000004001 serotonin 1D antagonist Substances 0.000 claims 1
- 229960002073 sertraline Drugs 0.000 claims 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 1
- 229960001685 tacrine Drugs 0.000 claims 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 1
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 claims 1
- 229960002004 valdecoxib Drugs 0.000 claims 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 1
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 claims 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
- 230000003313 weakening effect Effects 0.000 claims 1
- 0 *C(N(C1=NN2)C2=O)=C(*)N=C1N(*)* Chemical compound *C(N(C1=NN2)C2=O)=C(*)N=C1N(*)* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51022403P | 2003-10-10 | 2003-10-10 | |
| PCT/IB2004/003137 WO2005035532A1 (en) | 2003-10-10 | 2004-09-27 | Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007508290A JP2007508290A (ja) | 2007-04-05 |
| JP2007508290A5 true JP2007508290A5 (https=) | 2007-10-11 |
Family
ID=34435073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006530734A Pending JP2007508290A (ja) | 2003-10-10 | 2004-09-27 | ＧＳＫ−３阻害剤としての置換２Ｈ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7709473B2 (https=) |
| EP (1) | EP1678180B1 (https=) |
| JP (1) | JP2007508290A (https=) |
| AT (1) | ATE369370T1 (https=) |
| BR (1) | BRPI0415185A (https=) |
| CA (1) | CA2541832C (https=) |
| DE (1) | DE602004008098T8 (https=) |
| ES (1) | ES2288270T3 (https=) |
| MX (1) | MXPA06004043A (https=) |
| WO (1) | WO2005035532A1 (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004289638B2 (en) | 2003-11-04 | 2009-10-01 | Merck Sharp & Dohme Corp. | Substituted naphthyridinone derivatives |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| DE102007012645A1 (de) * | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Substituierte Imidazo- und Triazolopyrimidine |
| DE102007032349A1 (de) * | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
| WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| PE20091074A1 (es) * | 2007-12-13 | 2009-07-26 | Bayer Healthcare Ag | Triazolotriazinas y triazolopirazinas y su uso |
| DE102008023801A1 (de) | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| JP5559604B2 (ja) * | 2009-05-27 | 2014-07-23 | 富山化学工業株式会社 | ３，６−ジクロロ−２−ピラジンカルボニトリルの製造法 |
| EP2526102B1 (en) | 2010-01-22 | 2017-03-08 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Inhibitors of PI3 kinase |
| US20130131057A1 (en) | 2010-05-13 | 2013-05-23 | Centro Nacional De Investigaciones Oncologicas (Cnio | New bicyclic compounds as pi3-k and mtor inhibitors |
| CA2807546C (en) | 2010-08-10 | 2022-08-23 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| WO2013033461A1 (en) | 2011-08-31 | 2013-03-07 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
| US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| CN103121970B (zh) * | 2012-12-04 | 2015-04-29 | 中国科学院昆明植物研究所 | 苯并咪唑及其衍生物，其药物组合物及其在制备抗抑郁药物中的应用 |
| CN103121969A (zh) * | 2012-12-04 | 2013-05-29 | 中国科学院昆明植物研究所 | 苯并咪唑及其衍生物，其药物组合物及其应用 |
| US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| KR20150103269A (ko) | 2013-01-04 | 2015-09-09 | 렘펙스 파머수티클스 인코퍼레이티드 | 보론산 유도체 및 그의 치료적 용도 |
| US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| MX2015008627A (es) | 2013-01-04 | 2015-09-23 | Rempex Pharmaceuticals Inc | Derivados de acido boronico y usos terapeuticos de los mismos. |
| SI3105218T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot inhibitorji LSD1 |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| MX373103B (es) | 2014-02-13 | 2020-04-17 | Incyte Holdings Corp | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| EP3139930B1 (en) | 2014-05-05 | 2024-08-14 | Melinta Therapeutics, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
| ES2750805T3 (es) | 2014-05-05 | 2020-03-27 | Rempex Pharmaceuticals Inc | Síntesis de sales de boronato y usos de las mismas |
| AU2015264418A1 (en) | 2014-05-19 | 2016-11-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| BR112016029825B1 (pt) * | 2014-06-17 | 2020-10-27 | Cisen Pharmaceutical Co., Ltd. | composto |
| AU2015276699B2 (en) * | 2014-06-17 | 2019-10-10 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor |
| WO2016003929A1 (en) | 2014-07-01 | 2016-01-07 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US10662205B2 (en) | 2014-11-18 | 2020-05-26 | Qpex Biopharma, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| US20180051041A1 (en) | 2015-03-17 | 2018-02-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| LT3334709T (lt) | 2015-08-12 | 2025-03-10 | Incyte Holdings Corporation | Lsd1 inhibitoriaus druskos |
| JP6999574B2 (ja) | 2016-04-22 | 2022-01-18 | インサイト・コーポレイション | Ｌｓｄ１阻害剤の製剤 |
| MX389349B (es) | 2016-06-30 | 2025-03-20 | Qpex Biopharma Inc | Derivados de ácido borónico y usos terapéuticos de los mismos. |
| CN107602446B (zh) * | 2016-07-12 | 2020-04-07 | 中国科学院上海药物研究所 | 1,4-双取代-1,2,3,6-四氢吡啶类化合物、其制备方法、药物组合物及其应用 |
| KR102598895B1 (ko) | 2016-07-12 | 2023-11-07 | 레볼루션 메디슨즈, 인크. | 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진 |
| MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
| MX2019008696A (es) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
| US11286270B2 (en) | 2017-10-11 | 2022-03-29 | Qpex Biopharma, Inc. | Boronic acid derivatives and synthesis thereof |
| MX2020003579A (es) | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos. |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| WO2019156989A1 (en) * | 2018-02-06 | 2019-08-15 | Ideaya Biosciences, Inc. | COMPOUNDS AND METHODS FOR THE MODULATION OF AhR |
| EP3781576B1 (en) | 2018-04-20 | 2024-06-12 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| AU2021266715A1 (en) | 2020-05-05 | 2022-11-17 | Qpex Biopharma, Inc. | Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof |
| AR131541A1 (es) | 2023-01-07 | 2025-04-09 | Syngenta Crop Protection Ag | Compuestos de carboxamida novedosos |
| WO2025032129A1 (en) | 2023-08-08 | 2025-02-13 | Syngenta Crop Protection Ag | Novel aminoindane and aminotetraline compounds |
| WO2025109114A1 (en) | 2023-11-24 | 2025-05-30 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| PY2501648A (es) | 2024-01-12 | 2025-10-31 | Syngenta Crop Protection Ag | Nuevos compuestos de carboxamida |
| WO2025149637A1 (en) | 2024-01-12 | 2025-07-17 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2026008750A1 (en) | 2024-07-05 | 2026-01-08 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1235910A (en) * | 1968-12-10 | 1971-06-16 | Ici Ltd | Pharmaceutical compositions |
| FR2662163A1 (fr) * | 1990-05-16 | 1991-11-22 | Lipha | Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant. |
| JP2002297477A (ja) * | 2001-03-28 | 2002-10-11 | Sony Computer Entertainment Inc | 配信システム及び配信方法 |
| DE60232669D1 (de) * | 2001-04-30 | 2009-07-30 | Vertex Pharma | Inhibitoren von gsk-3 und kristallstrukturen von gsk-3beta-protein und -proteinkomplexen |
| EP1340759A1 (en) * | 2002-02-28 | 2003-09-03 | Sanofi-Synthelabo | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives |
| BRPI0407926A (pt) | 2003-03-27 | 2006-02-21 | Pfizer Prod Inc | 4-amino[1,2,4]triazol[4,3-a]quinoxalinas substituìdas |
-
2004
- 2004-09-27 CA CA002541832A patent/CA2541832C/en not_active Expired - Fee Related
- 2004-09-27 JP JP2006530734A patent/JP2007508290A/ja active Pending
- 2004-09-27 MX MXPA06004043A patent/MXPA06004043A/es not_active Application Discontinuation
- 2004-09-27 ES ES04769486T patent/ES2288270T3/es not_active Expired - Lifetime
- 2004-09-27 AT AT04769486T patent/ATE369370T1/de not_active IP Right Cessation
- 2004-09-27 US US10/575,395 patent/US7709473B2/en not_active Expired - Fee Related
- 2004-09-27 DE DE602004008098T patent/DE602004008098T8/de active Active
- 2004-09-27 EP EP04769486A patent/EP1678180B1/en not_active Expired - Lifetime
- 2004-09-27 WO PCT/IB2004/003137 patent/WO2005035532A1/en not_active Ceased
- 2004-09-27 BR BRPI0415185-2A patent/BRPI0415185A/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007508290A5 (https=) | ||
| JP2006521343A5 (https=) | ||
| CA2541832A1 (en) | Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors | |
| CN102171204B (zh) | 8位取代异喹啉衍生物及其用途 | |
| EP2114917B1 (en) | Pyrrole compounds | |
| JP4882748B2 (ja) | トリアゾール誘導体またはその塩 | |
| DK2432765T3 (en) | Isoquinolin-1 (2H) -ONE DERIVATIVES AS PARP-1 inhibitors | |
| CA2621181C (en) | 5-isoquinolinesulfonamide compounds | |
| US20040192701A1 (en) | Phenlypyridine carbonyl piperazine derivative | |
| WO2010114881A1 (en) | Anti-neoplastic compounds, compositions and methods | |
| ZA200406275B (en) | Substituted pyridinones as modulators of p38 map kinase | |
| JP2011506480A5 (https=) | ||
| JP2013532692A5 (https=) | ||
| JP2010505842A (ja) | トロンビン受容体拮抗薬としての二環式誘導体および三環式誘導体 | |
| JP2011511001A5 (https=) | ||
| JP5922128B2 (ja) | ヒスタミンｈ４受容体リガンドとしてのベンザゾール誘導体 | |
| US8765972B2 (en) | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides with selective PARP-1 inhibition | |
| WO2007043457A1 (ja) | トリアリールカルボン酸誘導体 | |
| TW200813070A (en) | Antiviral agents | |
| JP2008519087A5 (https=) | ||
| IL300502A (en) | Method and compound for use in the treatment and/or prevention of netosis | |
| WO2016118565A1 (en) | Quinazoline and quinoline compounds and uses thereof | |
| US9073893B2 (en) | 3-Oxo-2,3-dihydro-1H-indazole-4-carboxamide derivatives as PARP-1 inhibitors | |
| AU4373600A (en) | Combination therapy for the treatment of migraine | |
| JP2010520917A5 (https=) |